Previously, Dr. Kuldeep Neote was Vice President, External Innovation at Eli Lilly and responsible for Lilly’s New Venture initiative. During his tenure at Lilly, he focused on precision and genomic based therapeutics opportunities and enabled Lilly’s recent acquisition of Prevail Therapeutics. From 2013-2018, he was Senior Director, New Ventures at Johnson & Johnson Innovation and responsible for New Venture activities for the Janssen R&D in the East Coast.

He has established academic and biotech collaborations including two opportunities in Canada and served as the interim Head of JLABS@Canada. Prior to these leadership roles, he was Research Advisor/Director in Global External R&D at Eli Lilly in Indianapolis, IN and responsible for search and evaluation of Oncology in-licensing opportunities.

Prior to Eli Lilly, he was a Discovery Scientist in Pfizer Inc. in Groton, CT. Dr. Neote initiated the Chemokine Receptor Drug Discovery platform that led to several clinical candidates, and also discovered novel chemokines. Earlier in his career, Dr. Neote cloned one of the first chemokine receptors during his post-doctoral studies in Genentech.

Dr. Neote also consults for the life sciences healthcare sector, with an extensive background in implementing cutting edge scientific discoveries into practical drug discoveryprograms. He is also an Entrepreneur-in-Residence at the NIH, OICR/FACIT and UHN.

Dr. Neote earned his BSc. in Microbial and Cellular Biology at the University of Calgary, Calgary, Canada, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, Toronto, Canada, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff’s disease.